Results 61 to 70 of about 122,678 (147)

SnapShot: SARS-CoV-2 antibodies [PDF]

Cell Host & Microbe, 2021
Montefiori, David C., Acharya, Priyamvada   +1 more
openaire   +2 more sources

Efficient transplacental transfer of SARS-CoV-2 antibodies between naturally exposed mothers and infants in Accra, Ghana

Scientific Reports
We aimed to determine SARS-CoV-2 antibody seropositivity among pregnant women and the transplacental transfer efficiency of SARS-CoV-2-specific antibodies relative to malaria antibodies among SARS-CoV-2 seropositive mother-cord pairs.
Frederica D. Partey, Dorotheah Obiri, Evelyn Yayra Bonney, Abigail Naa Adjorkor Pobee, Isaac Kumi Damptey, Keren Ennuson, Jayln Akwetea-Foli, Franklin Yengdem Nuokpem, David Courtin, Kwadwo A. Kusi, Benedicta A. Mensah   +10 more
doaj   +1 more source

Joint Detection of Serum IgM/IgG Antibody Is an Important Key to Clinical Diagnosis of SARS-CoV-2 Infection

Canadian Journal of Infectious Diseases and Medical Microbiology, 2020
Background. This study was aimed to investigate the application of SARS-CoV-2 IgM and IgG antibodies in diagnosis of COVID-19 infection. Method. This study enrolled a total of 178 patients at Huangshi Central Hospital from January to February 2020. Among
Fang Hu, Xiaoling Shang, Meizhou Chen, Changliang Zhang   +3 more
doaj   +1 more source

Immunological assessment of SARS-CoV-2 infection in pregnancy from diagnosis to delivery: A multicentre prospective study.

PLoS ONE, 2021
BackgroundBackground Population-based data on SARS-CoV-2 infection in pregnancy and assessment of passive immunity to the neonate, is lacking. We profiled the maternal and fetal response using a combination of viral RNA from naso-pharyngeal swabs and ...
Kate Glennon, Jennifer Donnelly, Susan Knowles, Fionnuala M McAuliffe, Alma O'Reilly, Siobhan Corcoran, Jennifer Walsh, Roger McMorrow, Tess Higgins, Lucy Bolger, Susan Clinton, Sarah O'Riordan, Alexander Start, Doireann Roche, Helena Bartels, Ciara Malone, Karl McAuley, Anthony McDermott, Rosanna Inzitari, Colm P F O'Donnell, Fergal Malone, Shane Higgins, Cillian De Gascun, Peter Doran, Donal J Brennan   +24 more
doaj   +1 more source

Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus

Heliyon, 2023
The human infectious disease COVID-19 caused by the SARS-CoV-2 virus has become a major threat to global public health. Developing a vaccine is the preferred prophylactic response to epidemics and pandemics.
Nancy E. Hernandez, Wojciech Jankowski, Rahel Frick, Simon P. Kelow, Joseph H. Lubin, Vijaya Simhadri, Jared Adolf-Bryfogle, Sagar D. Khare, Roland L. Dunbrack, Jr., Jeffrey J. Gray, Zuben E. Sauna   +10 more
doaj   +1 more source

Neutralizing antibodies targeting SARS-CoV-2 spike protein

Stem Cell Research, 2021
SARS-CoV-2 causing the worldwide pandemic has changed people's life in multiple aspects dramatically since it's first identified in Wuhan, China at the end of 2019. While the numbers of infected patients and death toll keep vigorous increasing, curbing the progression of the pandemic is an urgent goal.
Xiaojie, Shi, Yu, Li, lei, Yan, Guang, Yang, Min, Qiang   +4 more
openaire   +3 more sources

Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins

Scientific Reports, 2021
Infection by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes COVID-19 disease. Therapeutic antibodies are being developed that interact with the viral spike proteins to limit viral infection of epithelium. We have applied a method
Adam Leach, Ami Miller, Emma Bentley, Giada Mattiuzzo, Jemima Thomas, Craig McAndrew, Rob Van Montfort, Terence Rabbitts   +7 more
doaj   +1 more source

Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies

International Journal of Molecular Sciences, 2022
Since the first COVID-19 reports back in December of 2019, this viral infection caused by SARS-CoV-2 has claimed millions of lives. To control the COVID-19 pandemic, the Food and Drug Administration (FDA) and/or European Agency of Medicines (EMA) have granted Emergency Use Authorization (EUA) to nine therapeutic antibodies.
Juan C. Almagro, Gabriela Mellado-Sánchez, Martha Pedraza-Escalona, Sonia M. Pérez-Tapia   +3 more
openaire   +2 more sources

Seroprevalence of Anti-SARS-Cov-2 IgG Antibodies in Tertiary Care Hospital [PDF]

Walawalkar International Medical Journal, 2021
Background: Seroprevalence of anti-SARS-CoV-2 IgG antibodies not only provides information for tracing the missing cases but also help in implying proper measures against the infection.
Rajendra Surpam1, Pooja Taiwade1, Bhausaheb Munde1 and Virendra Kolhe1
doaj  

SARS-CoV-2 Neutralizing Antibodies 2.0

Viruses
As the SARS-CoV-2 mutates, especially into those variants causing immune escape, COVID-19 continues to wreak havoc [...]
openaire   +3 more sources